selected publications
-
academic article
-
1560PDMajor determinants of delayed access to innovative medicines for metastatic melanoma: The results of Melanoma World Society and European Association of Dermato-Oncology survey.
Annals of Oncology.
29.
2018
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries..
Journal of Clinical Oncology.
36.
2018
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017.
European Journal of Cancer.
77.
2017
Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016.
Journal of Translational Medicine.
15.
2017
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.
The Lancet Oncology.
18.
2017
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials.
JAMA Oncology.
3.
2017
Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology.
Journal of Dermatological Treatment.
28.
2017
1389O_PR More than 5000 patients with metastatic melanoma in Europe per year do not have access to new life-saving drugs.
Annals of Oncology.
27.
2016
LBA2_PR melanoma and other skin tumours Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial.
Annals of Oncology.
27.
2016
Melanoma and immunotherapy bridge 2015.
Journal of Translational Medicine.
14.
2016
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
The Lancet Oncology.
16.
2015
Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial..
Journal of Clinical Oncology.
32.
2014
Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial..
Journal of Clinical Oncology.
32.
2014